NeuroMetrix to Exhibit at AACE Annual Meeting
WALTHAM, Mass.--(BUSINESS WIRE)--May. 23, 2012--
NeuroMetrix, Inc. (Nasdaq: NURO),
www.neurometrix.com,
a medical device company focused on the diagnosis and treatment of the
neurological complications of diabetes, reported today that it will be
an exhibitor at the
American Association of Clinical Endocrinologists’
(AACE) 21
st Annual
Scientific and Clinical Congress. The AACE
Annual Meeting will be held at the Marriott Philadelphia Downtown and
The Pennsylvania Convention Center.
NeuroMetrix will feature the NC-stat® DPNCheck™, a
medical device providing a fast, accurate, and quantitative
point-of-care test for the detection of systemic neuropathies such as
diabetic peripheral neuropathy (DPN). DPN affects over 50% of people
with diabetes and can lead to foot ulcers and amputation. Since
commercial launch of NC-stat DPNCheck in late 2011, the company has
attracted an expanding customer base of physicians, including
endocrinologists. NC-stat DPNCheck is also being successfully introduced
into managed care and retail health organizations.
The company will also discuss the SENSUS™ pain management
device which is under development and is designed to help patients
manage chronic pain, such as painful diabetic neuropathy. NeuroMetrix
recently filed a 510(k) premarket notification with the Food and Drug
Administration (FDA) for SENSUS. The device has not been cleared by FDA
and is not available for commercial distribution.
“The AACE Annual Meeting is an important event for endocrinologists,
including those with a practice focus on diabetes,” said Shai N. Gozani,
M.D., Ph.D., President and Chief Executive Officer, NeuroMetrix. “This
meeting provides us the opportunity to discuss with the endocrinology
community our approaches to DPN, which is one of the leading
complications of diabetes.”
About NeuroMetrix
NeuroMetrix is an innovative medical device company that develops and
markets home use and point-of-care devices, associated consumables, and
support software for the treatment and management of diabetes and its
complications. The company is focused on nerve related complications of
diabetes, called diabetic neuropathies, which affect over 50% of people
with diabetes. If left untreated, diabetic neuropathies trigger foot
ulcers that may require amputation, cause disabling pain, and increase
the risk of falling in the elderly. The annual cost of diabetic
neuropathies has been estimated at $14 billion in the United States. The
company’s products are used by physicians and other clinicians, in
retail health settings such as pharmacies, and by managed care
organizations to optimize patient care and reduce healthcare costs. The
company markets the NC-stat® DPNCheck™ device,
which is a rapid, accurate, and quantitative point-of-care test for
diabetic neuropathy. This product is used to detect diabetic neuropathy
at an early stage and to guide treatment. The company is in late stage
development of SENSUS™, a pain management device that will be
used to treat painful diabetic neuropathy, a form of chronic intractable
pain. Currently, painful diabetic neuropathy is treated
pharmacologically, which is a $2 billion annual market. The company has
additional therapeutic products in its pipeline. For more information,
please visit http://www.neurometrix.com.
Source: NeuroMetrix
NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
Chief
Financial Officer
neurometrix.ir@neurometrix.com
